Cost-effectiveness of Eylea Monotherapy vs. Bevacizumab-first Strategy for Treating Diabetic Macular Edema | ASRS 2023
Research shows a $12,575 savings over two years and no difference in outcome, which result in an incremental cost-effectiveness ratio (ICER) of $873,000.
A cost-effectiveness comparison between monotherapy with Eylea for diabetic macular edema and starting off-label bevacizumab first and switching patients to Eylea if need be showed that the bevacizumab-first strategy was far more cost effective, according to results presented by Matthew W. MacCumber, M.D., Ph.D., today at the American Society of Retinal Specialists annual scientific meeting in Seattle.
But in an interview prior to the meeting, MacCumber said that the results should be applied with caution and should be extended to other retinal diseases.
“Diabetic macular edema is a forgiving disorder,” said MacCumber, of Illinois Retina Specialists and a professor and director of research for the Department of Ophthalmology at Rush University Medical Center in Chicago. “Other conditions in the retina, for instance age-related macular degeneration, if you lose that benefit (of anti-VEGF treatment) early on, you may never get it back.”
Bevacizumab, sold under the brand-name Avastin, has been used off-label and repackaged by retinal specialists for many years.
Changes to Susvimo Port Delivery System Explained | ASRS 2024
July 22nd 2024Dante J. Pieramici, M.D., of the California Retina Research Foundation, explains changes made to the Susvimo port delivery system that are designed. to prevent the septum dislodgment that led to Genentech pulling the product off the market.
Read More
Results from retrospective real-world studies presented at American Society of Retina Specialists annual meetiing put the risk of retinal vasculitis from Syfovre at 1 in 1,330 patients. But other results presented at the meeting supplied evidence that Syfovre fends off vision loss caused by geographic atrophy, an advanced form of dry age-related macular degeneration.
Read More
